期刊
IMMUNOBIOLOGY
卷 222, 期 11, 页码 989-997出版社
ELSEVIER GMBH, URBAN & FISCHER VERLAG
DOI: 10.1016/j.imbio.2017.06.002
关键词
Delivery system; Targeting; Dendritic cells; Peptide vaccines; Immunotherapeutic vaccines; Cancer vaccines
类别
资金
- CICYT [CTQ2009-07758, CTQ2008-00177]
- Instituto de Salud Carlos III [CB06_01_0074]
- IV Convocatoria de Ayudas a la Investigacion de la Fundacion Mutua Madrilena
- Generalitat de Catalunya [2009SGR 1024, 2009SGR 367]
Nanoliposomes (NLs) hold promise as new highly specific nanomedicine for anti-tumor vaccines, since they could be targeted to specific receptors on dendritic cell (DC) to induce maturation and activation and increase the anti-tumor immune response. Here we studied a NLs formulation targeted or not to FcR (the receptor for the IgG Fc fragment) for the treatment of androgen-responsive prostate cancer. Luteinizing-hormone-releasing hormone (LHRH) peptide (B- and T-cell epitopes), in tandem with a tetanus toxoid T-helper epitope (830-844 region) and several TLR (Toll-Like Receptor) ligands as adjuvants were co-encapsulated. Specific uptake in vitro of LHRH-TT liposomes targeted to the FcRs of human DCs was enhanced. DC maturation/activation, cytokine production and lymphocyte activation were consistently higher in targeted than non-targeted liposomes. Similar increase was observed as more adjuvants were administrated. Targeting to specific receptor and co-encapsulation of several TLR adjuvants are essential factors for the immune response in peptide based liposome vaccine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据